Positive in vitro interactions with β-lactam linked to lower 14-day mortality in MRSA bacteraemiaPositive lab interactions linked to lower early death in MRSA infection treatment

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases Published May 1, 2026 Study authors: Soo Joel Z Y, Lim Tze-Peng, Ho Jayden J Y, Tong Steven Y C, Lye David C, Davis Joshua S, Kwa Andrea … PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider that positive in vitro interactions may predict early benefit from combination therapy in MRSA bacteraemia, but findings are hypothesis generating.

This post hoc analysis of a multicentre randomized trial evaluated the association between in vitro interaction results and clinical outcomes in 150 adults with MRSA bacteraemia who received combination therapy with vancomycin or daptomycin plus an antistaphylococcal β-lactam. Of 174 combination-therapy patients, 24 were excluded. Patients were categorized based on positive (synergy or additivity) or negative (antagonism or indifference) in vitro interactions.

The primary outcome, 90-day mortality, did not differ significantly between groups: 34% (16 of 47) in the positive interaction group vs. 32% (33 of 103) in the negative interaction group (p=0.81). However, 14-day all-cause mortality was significantly lower in the positive interaction group: 2.9% (3 of 103) vs. 12.8% (6 of 47) (p=0.03). Persistent bacteraemia at day 2 was numerically higher in the positive interaction group (32.0% vs. 19.1%, p=0.10).

Safety data were not reported. The authors note that these findings should be interpreted with caution and are considered hypothesis generating. Combination therapy may be beneficial when positive interactions are present but is not universally effective. Synergy testing may help optimize combination therapy, but confirmation in a randomized trial is warranted.

Limitations include the post hoc design and small sample size. The association between positive in vitro interactions and lower 14-day mortality does not imply causation. Clinicians should consider these results as preliminary and await further evidence before changing practice.

Doctors often mix antibiotics to fight tough infections like MRSA. But does the lab test prove the mix will work in a person? A new look at patient data suggests the answer might be yes for some cases. Researchers analyzed results from 150 adults with MRSA bloodstream infections. They compared patients whose drug combinations showed strong lab activity against those with weak lab activity. The main question was whether this lab signal predicted better survival.

The group with strong lab activity saw a significant drop in deaths within 14 days. Only three patients died in this group compared to nearly thirteen in the other group. However, the overall death rate at 90 days was similar for both groups. The team also found that infections cleared slightly slower in the strong lab activity group, though this difference was not statistically significant.

This analysis was not a new trial but a review of existing data. The researchers call these results hypothesis generating. They warn that positive lab results do not guarantee success for every patient. Combination therapy may be beneficial when positive interactions are present, but it is not universally effective. Future randomized trials are needed to confirm if testing lab interactions can truly guide better treatment choices.

What this means for you:

Strong lab drug interactions linked to lower early death in some MRSA patients, but results need confirmation.

Study Details

Study typeRct

Sample sizen = 150

EvidenceLevel 2

PublishedMay 2026

PMID41679464

View Original Abstract ↓

OBJECTIVE: Combination antibiotic therapy may improve treatment success for bacterial infections, but bacterial strain-to-strain variability in synergy and its clinical impact remains unclear. This study evaluated whether positive in vitro interactions (synergy or additivity) between vancomycin or daptomycin and a β-lactam in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections are associated with improved clinical outcomes in the Combination Antibiotic for Methicillin Resistant Staphylococcus aureus (CAMERA2) trial. METHODS: In this post hoc analysis of the multicentre randomized CAMERA2 trial, adults with MRSA bacteraemia were randomly assigned to standard care (vancomycin or daptomycin) or combination therapy with an antistaphylococcal β-lactam. Of 174 combination-therapy patients, 24 were excluded for unavailable isolates or missing outcome data, leaving 150 for analysis. Synergy testing was performed centrally, post hoc, using a microdilution checkerboard assay, stratifying patients into positive interaction (synergy/additivity) and negative interaction (antagonism/indifference) groups. Clinical outcomes-including primary composite end point of 90-day mortality-were compared between groups, using statistical tests and multivariate regression adjusting for confounders. RESULTS: Among 150 patients, 103 were in the positive interaction group and 47 in the negative interaction group. Patient characteristics were similar. The primary composite endpoint of 90-day mortality (34% [16 of 47] vs. 32% [33 of 103], p 0.81) did not differ significantly between groups. Persistent bacteraemia rate at day 2 was higher (32.0% [33 of 103] vs. 19.1% [9 of 47], p 0.10) in the positive interaction group. However, 14-day all-cause mortality was significantly lower in the positive interaction group (2.9% [3 of 103] vs. 12.8% [6 of 47], p 0.03). CONCLUSIONS: Positive interactions between vancomycin or daptomycin and a β-lactam were associated with lower 14-day mortality in MRSA bacteraemia. However, these findings should be interpreted with caution and considered hypothesis generating. Combination therapy may be beneficial when positive interactions are present, not universally effective. Synergy testing may help optimize combination therapy, warranting confirmation in a randomized trial.

Positive in vitro interactions with β-lactam linked to lower 14-day mortality in MRSA bacteraemiaPositive lab interactions linked to lower early death in MRSA infection treatment

Study Details

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

Clinical research that matters. Delivered to your inbox.

Positive in vitro interactions with β-lactam linked to lower 14-day mortality in MRSA bacteraemiaPositive lab interactions linked to lower early death in MRSA infection treatment

More on methicillin-resistant Staphylococcus aureus bacteraemia

Study Details

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

Clinical research that matters. Delivered to your inbox.

Related in Infectious Disease

From Other Specialties